Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study

作者：Sailish Honap, María José Temido, Eathar Shakweh, Fakhirah Badrulhisham, Natalie Shields, Sonia Mehta, Jodie McBride, Mathieu Uzzan, Milan Lukáš, Mathurin Fumery, Akira Nogami, Taku Kobayashi, Stéphane Nancey, Joana Camões Neves, João Martins Mendes, Birte-Antina Wegener, Emilie Bergereau, Rita de Cássia Leite Fernandes, Anish John Kuriakose Kuzhiyanjal, Sophie Vieujean, Ashley Spencer, Samantha Baillie, Maria Manuela Estevinho, Inês Simão, Catarina O’Neill, Madalina Gututui, Ellen Thompson, Amina Jama, Ningyu Chai, Polychronis Pavlidis, Ferdinando D’Amico, Jimmy K. Limdi, Fernando Magro, Shaji Sebastian, Jonathan Digby‐Bell, Gareth Parkes, Shahida Din, Ailsa Hart, Laurent Peyrin-Biroulet · 发表于：Clinical Gastroenterology and Hepatology · 年份：2025 · DOI：10.1016/j.cgh.2025.04.031 · 被引用次数：20 · 研究领域：Acne and Rosacea Treatments and Effects、Hidradenitis Suppurativa and Treatments、Psoriasis: Treatment and Pathogenesis

BACKGROUND & AIMS: JAK inhibitor-associated acne is a common but poorly understood adverse event. This study aimed to investigate the epidemiology, clinical characteristics, and treatment outcomes of this condition in patients with inflammatory bowel disease (IBD). METHODS: This international, multicenter, retrospective cohort study consecutively enrolled JAK-inhibitor-treated patients with IBD who subsequently developed acne. The primary objective was to evaluate the clinical characteristics of acne. Secondary objectives included determining acne prevalence, impact on quality of life, and antiacne treatment effectiveness. RESULTS: Among 2183 JAK inhibitor-treated patients with IBD, 272 developed acne. The crude prevalence rates of acne were 15.9% for upadacitinib, 4.3% for tofacitinib, and 1.9% for filgotinib, with dose-dependent relationships observed for upadacitinib and tofacitinib. Acne predominantly affected patients aged 30-50 years; most cases were mild-moderate in severity. A prior history of acne vulgaris was associated with significantly increased odds of developing severe JAK inhibitor-associated acne (odds ratio, 4.88; 95% confidence interval, 2.88-31.7; P = .0003) and acne-related skin complications (odds ratio, 3.92; 95% confidence interval, 1.56-10.11; P = .004). One-third of patients reported a negative psychosocial impact, and 40% received pharmacologic intervention. Eighteen percent of patients who developed acne required JAK inhibitor dose reduction or dis...